Forekomsten af bivirkninger og unormale laboratoriefund (bortset fra stigninger i ALAT og CPK se nedenfor) var ens mellem de patienter, som blev behandlet med henholdsvis lamivudin og placebo.
The incidence of adverse events and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients).